2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
You are currently not logged in to PHD
To view this content, please login to your account, or within the login, click 'Create an Account' for guest access.
Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
Steve Ommen, MD, FACC from the Mayo Clinic and Carolyn Ho, MD, FAHA from Brigham and Women's Hospital discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. They highlight the introduction of Mavacamten, the first cardiac myosin inhibitor, as a significant change following its FDA approval for symptomatic obstructive HCM.
Recommended Videos
Training Pathways in the Evolution of Critical Care Cardiology
What is Environmental Crisis Exposome?
External Environmental Exposures Impacts on Health
Evaluating Kidney Dysfunction in Patients with Advance Heart Failure: Over...
Impacts of Wildfires on Health and in High Risk Populations
Loading...
Save Video
Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
Video is not available. Please check the URL.